Disc Medicine Inc. (IRON) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Disc Medicine Inc. (IRON) has a cash flow conversion efficiency ratio of -0.069x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.20 Million) by net assets ($644.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Disc Medicine Inc. (IRON) total market value for the company's overall valuation and market capitalisation.
Disc Medicine Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Disc Medicine Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Disc Medicine Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Disc Medicine Inc. ranked by their cash flow conversion efficiency. See Disc Medicine Inc. debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Dongyue Organosilicon Mat
SHE:300821
|
-0.009x |
|
Shanghai Yuyuan Tourist Mart Co Ltd
SHG:600655
|
0.041x |
|
Danaos Corporation
NYSE:DAC
|
0.049x |
|
Zhejiang Kaishan Compressor
SHE:300257
|
0.028x |
|
Clearway Energy Inc Class C
NYSE:CWEN
|
0.030x |
|
KWS SAAT SE & Co. KGaA
F:KWS
|
-0.054x |
|
Guangshen Railway Co Ltd
SHG:601333
|
0.009x |
|
Tongling Jingd
SHG:600577
|
0.065x |
Annual Cash Flow Conversion Efficiency for Disc Medicine Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Disc Medicine Inc. from 2020 to 2025. View Disc Medicine Inc. (IRON) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $739.83 Million | $-180.39 Million | -0.244x | -15.16% |
| 2024-12-31 | $443.59 Million | $-93.93 Million | -0.212x | +0.52% |
| 2023-12-31 | $345.12 Million | $-73.46 Million | -0.213x | +11.03% |
| 2022-12-31 | $176.60 Million | $-42.25 Million | -0.239x | -155.79% |
| 2021-12-31 | $-64.20 Million | $-27.53 Million | 0.429x | -71.34% |
| 2020-12-31 | $-21.86 Million | $-32.71 Million | 1.496x | -- |
About Disc Medicine Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associ… Read more